Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.

Biomolecules - 18 May 2021

Zakaria Nur Atikah, Islam Md Asiful, Abdullah Wan Zaidah, Bahar Rosnah, Mohamed Yusoff Abdul Aziz, Abdul Wahab Ridhwan, Shamsuddin Shaharum, Johan Muhammad Farid

Abstract excerpt

Thalassemia, an inherited quantitative globin disorder, consists of two types, α- and β-thalassemia. β-thalassemia is a heterogeneous disease that can be asymptomatic, mild, or even severe. Considerable research has focused on investigating its underlying etiology. These studies found that DNA hypomethylation in the β-globin gene cluster is significantly related to fetal hemoglobin (HbF) elevation. Histone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantigens
Share to beta-Globins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Thalassemia

Share to Epigenesis, Genetic

Share to Histone Code

Share to Molecular Targeted Therapy

Share to Ribonucleoproteins

Share to RNA, Untranslated

Source

Open in PubMed Open full text

Identifiers

PMID: 34070036
DOI: 10.3390/biom11050755
PMCID: PMC8158146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.PMID 34070036Read ↗

Molecular basis of β thalassemia and potential therapeutic targets.Semantic proximity Read ↗

2017 Clinical trials update in new treatments of β‐thalassemiaSemantic proximity Read ↗

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell DiseaseSemantic proximity Read ↗

Molecular genetics of β-thalassemiaSemantic proximity Read ↗

Single Nucleotide Polymorphisms in XMN1-HBG2, HBS1L-MYB, and BCL11A and Their Relation to High Fetal Hemoglobin Levels That Alleviate AnemiaSemantic proximity Read ↗

α-Globin as a molecular target in the treatment of β-thalassemiaSemantic proximity Read ↗

Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease.Semantic proximity Read ↗

Thalassemias: from gene to therapy.Semantic proximity Read ↗

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read ↗

Dissecting the role of genetic modifiers of hemoglobinopathies: A futuristic approach towards precision medicineSemantic proximity Read ↗

Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approachesSemantic proximity Read ↗

Novel genetic therapeutic approaches for modulating the severity of β‑thalassemia (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.